A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

(MENAFN- GlobeNewsWire - Nasdaq) Explore the GLP-1R agonists market, uncovering new opportunities for repurposing beyond type 2 diabetes and obesity ... Novo Nordisk and Eli Lilly and potential ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Thanks to these recent developments, Eli Lilly could take the lead in this fast-growing market. The company's ... obstructive sleep apnea in adults with obesity. In November, it announced it ...

While Eli Lilly entered the market later, it is emerging as the ... "While Novo [Nordisk] took a commanding early lead in the obesity duopoly, they have ceded ground at a critical moment when ...

Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.